| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_62be1bb5b9ad4185e041f0ce0dfc0c12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4d33e45e5cbd64b8b893bd62ee22a85b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9c37762188a56acca3ecbc14acf8881b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_892c32b2a87ebf4943228911801a9e80 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-33 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate |
2022-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a706324257af6860eb7ca6efdb645bdb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d21c8c1bd8a70e7ed163afd0c922dba9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0359f6ee71f6ce17819bc746099a5cb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_814c7591964ac2823d0cbfa9760ca929
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbbb4163df1590572e2d1e48838586e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_536cbc4ff479f5468e7cd954aa2d69e5 |
| publicationDate |
2022-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022223488-A1 |
| titleOfInvention |
Use of splice switching oligonucleotides for exon skipping-mediated knockdown of pim2 |
| abstract |
PIM2 kinase deregulation has been reported in several cancers. In particular, PIM2 is considered in multiple myeloma as part of the oncogenic process and several PIM kinase inhibitors have been developed showing encouraging results in preclinical studies and clinical trials. Now the inventors have developed an antisense RNA strategy based on a splice-switching oligonucleotide (SSO) so as to induce efficient knockdown of PIM2 expression. This SSO-mediated knockdown is a powerful approach to for cancer treatments. Accordingly, the present invention relates to the use of splice switching oligonucleotides for exon skipping-mediated knockdown of PIM2. |
| priorityDate |
2021-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |